ECSP16089579A - Proteínas agonistas de los receptores de trail de cadena simple. - Google Patents

Proteínas agonistas de los receptores de trail de cadena simple.

Info

Publication number
ECSP16089579A
ECSP16089579A ECIEPI201689579A ECPI201689579A ECSP16089579A EC SP16089579 A ECSP16089579 A EC SP16089579A EC IEPI201689579 A ECIEPI201689579 A EC IEPI201689579A EC PI201689579 A ECPI201689579 A EC PI201689579A EC SP16089579 A ECSP16089579 A EC SP16089579A
Authority
EC
Ecuador
Prior art keywords
proteins
agonists
trail
single chain
trail receptors
Prior art date
Application number
ECIEPI201689579A
Other languages
English (en)
Inventor
Christian Gieffers
Meinolf Thiemann
Darren C Phillips
Susan E Lappe
Oliver Hill
Fritz Buchanan
Original Assignee
Apogenix Ag
Potisek Stephanie L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag, Potisek Stephanie L filed Critical Apogenix Ag
Publication of ECSP16089579A publication Critical patent/ECSP16089579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)

Abstract

Proteínas específicas que son agonistas de los receptores de TRAIL. Ácidos nucleicos que las codifican. Métodos para tratar una enfermedad o un trastorno asociado a los TRAIL en un sujeto. Las proteínas agonistas de los receptores de TRAIL que se proveen en la presente comprenden tres dominios de TRAIL solubles y un fragmento Fc. Las proteínas agonistas de los receptores de TRAIL no forman agregados de manera sustancial y son apropiadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.
ECIEPI201689579A 2014-04-23 2016-11-23 Proteínas agonistas de los receptores de trail de cadena simple. ECSP16089579A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
ECSP16089579A true ECSP16089579A (es) 2018-05-31

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201689579A ECSP16089579A (es) 2014-04-23 2016-11-23 Proteínas agonistas de los receptores de trail de cadena simple.

Country Status (37)

Country Link
US (4) US9908927B2 (es)
EP (2) EP3134430B1 (es)
JP (2) JP6523331B2 (es)
KR (2) KR102079919B1 (es)
CN (2) CN106459221B (es)
AR (1) AR100168A1 (es)
AU (3) AU2015249649B2 (es)
BR (1) BR112016024515B1 (es)
CA (2) CA2946402C (es)
CL (1) CL2016002683A1 (es)
CR (1) CR20160516A (es)
CY (1) CY1120281T1 (es)
DK (1) DK3134430T3 (es)
DO (1) DOP2016000284A (es)
EC (1) ECSP16089579A (es)
ES (1) ES2672368T3 (es)
HR (1) HRP20180950T1 (es)
HU (1) HUE038914T2 (es)
IL (2) IL248244B (es)
LT (1) LT3134430T (es)
MA (2) MA45069A (es)
MX (2) MX2016013858A (es)
MY (1) MY181986A (es)
NO (1) NO2776305T3 (es)
PE (1) PE20170299A1 (es)
PH (1) PH12016502079B1 (es)
PL (1) PL3134430T3 (es)
PT (1) PT3134430T (es)
RS (1) RS57153B1 (es)
RU (1) RU2699285C2 (es)
SG (3) SG10202111785VA (es)
SI (1) SI3134430T1 (es)
TR (1) TR201806912T4 (es)
TW (2) TWI683825B (es)
UA (1) UA118286C2 (es)
UY (1) UY36095A (es)
WO (1) WO2015164588A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709355B (zh) * 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
CN108699129A (zh) 2015-10-23 2018-10-23 阿珀吉科吉尼科斯股份公司 单链light受体激动剂蛋白
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
US20190077870A1 (en) * 2016-03-16 2019-03-14 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
AU2018313253A1 (en) * 2017-08-11 2020-02-27 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178433A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
TW202003553A (zh) * 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
EP4346885A1 (en) 2021-05-28 2024-04-10 Julius-Maximilians-Universität Würzburg Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003091447A2 (en) 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
JP2008535909A (ja) * 2005-04-15 2008-09-04 ラパポート ファミリー インスティテュート フォー リサーチ イン ザ メディカル サイエンシーズ Ｍｃｐ−１／ｃｃｒ２関連疾患を治療するための分子およびその使用方法
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP2484691B1 (en) 2007-07-10 2016-01-13 Apogenix GmbH TNF superfamily collectin fusion proteins
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
EP3103875A1 (en) 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
AU2009303304A1 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
ES2593049T3 (es) 2009-01-09 2016-12-05 Apogenix Ag Proteínas de fusión que forman trímeros
MX2011007833A (es) * 2009-01-23 2011-10-06 Biogen Idec Inc Polipeptidos fc estabilizados con funcion efectora reducida y metodos de uso.
CA2785139A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
US20130079280A1 (en) * 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
WO2013092998A1 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
DK2875045T3 (en) * 2012-07-18 2018-07-02 Apogenix Ag COMPOSITION comprising a mixture of CD95-FC ISOFORMs

Also Published As

Publication number Publication date
RU2699285C2 (ru) 2019-09-04
TW202024123A (zh) 2020-07-01
AU2020202247A1 (en) 2020-04-23
MX2016013858A (es) 2017-08-02
TWI683825B (zh) 2020-02-01
US20150337027A1 (en) 2015-11-26
JP2019162114A (ja) 2019-09-26
RU2016145608A3 (es) 2018-12-26
ES2672368T3 (es) 2018-06-14
CA2946402C (en) 2023-02-28
MA39770A (fr) 2015-10-29
CN111718424A (zh) 2020-09-29
KR20170012257A (ko) 2017-02-02
BR112016024515A2 (pt) 2017-10-10
HRP20180950T1 (hr) 2018-08-10
EP3134430B1 (en) 2018-03-21
AR100168A1 (es) 2016-09-14
WO2015164588A1 (en) 2015-10-29
SG10202111785VA (en) 2021-12-30
BR112016024515B1 (pt) 2020-03-31
AU2015249649B2 (en) 2018-10-04
CR20160516A (es) 2017-05-10
CN106459221B (zh) 2020-09-01
JP2017513503A (ja) 2017-06-01
MX2019013587A (es) 2020-01-13
CA2946402A1 (en) 2015-10-29
EP3134430A1 (en) 2017-03-01
US9908927B2 (en) 2018-03-06
US20210040178A1 (en) 2021-02-11
IL248244B (en) 2020-03-31
SG11201608767XA (en) 2016-11-29
AU2018271369A1 (en) 2018-12-20
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
SI3134430T1 (en) 2018-05-31
CL2016002683A1 (es) 2017-07-07
RU2016145608A (ru) 2018-05-28
MY181986A (en) 2021-01-18
PH12016502079A1 (en) 2016-12-19
DOP2016000284A (es) 2017-02-15
PH12016502079B1 (en) 2016-12-19
UA118286C2 (uk) 2018-12-26
US20180222962A1 (en) 2018-08-09
PL3134430T3 (pl) 2018-08-31
AU2015249649A1 (en) 2016-11-10
NO2776305T3 (es) 2018-01-27
JP6523331B2 (ja) 2019-05-29
AU2018271369B2 (en) 2020-01-02
US20240174731A1 (en) 2024-05-30
CY1120281T1 (el) 2019-07-10
NZ725476A (en) 2023-09-29
TWI747178B (zh) 2021-11-21
EP3366699A1 (en) 2018-08-29
JP6714751B2 (ja) 2020-06-24
DK3134430T3 (en) 2018-05-22
PT3134430T (pt) 2018-04-20
IL248244A0 (en) 2016-11-30
TW201620928A (zh) 2016-06-16
MA45069A (fr) 2019-04-03
SG10201806465TA (en) 2018-08-30
IL272612A (en) 2020-03-31
KR20190135546A (ko) 2019-12-06
KR102079919B1 (ko) 2020-02-24
HUE038914T2 (hu) 2018-12-28
LT3134430T (lt) 2018-05-10
PE20170299A1 (es) 2017-05-06
RS57153B1 (sr) 2018-07-31
UY36095A (es) 2015-10-30
TR201806912T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
ECSP16089579A (es) Proteínas agonistas de los receptores de trail de cadena simple.
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CY1126115T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201791882A1 (ru) Агонисты 5ht для лечения нарушений
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
DK3293202T3 (da) Anti human interleukin-1 receptor accessory protein (il1rap) antibodies and uses thereof
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
ES2970391T3 (es) Sistemas, dispositivos y métodos para detectar fertilidad y género de huevos sin eclosionar
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
UY35835A (es) Anticuerpos específicos para FcRn.
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
MX2019006597A (es) Terapia basada en células nk mejoradas.
CL2016003038A1 (es) Dispositivo y procedimiento para la determinación de antígenos de grupo sanguíneo con un anticuerpo incompleto.
CL2015002365A1 (es) Métodos para uso de semen sexado para mejorar la gestión genética en cerdos